Barbara Pro, MD
Philadelphia, PA 19107
Most Recent Peer-reviewed Publications
- 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease
- Paclitaxel, topotecan and rituximab: Long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
- Clinical features, management and prognosis of multifocal primary bone lymphoma: A retrospective study of the international extranodal lymphoma study group (the IELSG 14 study)
- Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses
- Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
University of Rome, Italy - 1988
Mount Sinai Medical Center, NY
MD Anderson Cancer Center, Houston, TX
Thomas Jefferson University Hospital
Methodist Hospital Division of Thomas Jefferson University Hospital
Professor of Medical Oncology
Research & Clinical Interests
My laboratory research program focuses on the treatment of patients with lymphomas, including Hodgkin and non-Hodgkin lymphoma. I have played a major role in clinical trials for the application of targeted therapeutic agents in lymphoma, with one recent study demonstrating efficacy of the mTOR inhibitor temsirolimus in specific forms of non-mantle cell non-Hodgkin’s lymphoma. We are also interested in hepatosplenic gamma-delta T-cell lymphoma, a rare peripheral T cell lymphoma that does not respond to standard antracycline-containing chemotherapy: our work is helping to define the clinical features of patients with better versus poorer clinical prognosis. One of our important goals in clinical research is to develop effective new combination therapies in conjunction with the creation of efficient scoring systems for patient prognosis, to maximize the response of each patient to treatment.